Technical Analysis for BTX - BioTime, Inc.

Grade Last Price % Change Price Change
grade F 1.0 -6.54% -0.07
BTX closed down 6.54 percent on Friday, January 18, 2019, on 1.31 times normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical BTX trend table...

Date Alert Name Type % Chg
Jan 18 Fell Below 20 DMA Bearish 0.00%
Jan 18 Wide Bands Range Expansion 0.00%
Jan 17 Pocket Pivot Bullish Swing Setup -6.54%
Jan 17 Wide Bands Range Expansion -6.54%
Jan 16 180 Bearish Setup Bearish Swing Setup -5.66%
Jan 16 Wide Bands Range Expansion -5.66%
Jan 15 Inside Day Range Contraction -10.71%
Jan 15 Wide Bands Range Expansion -10.71%
Jan 15 Overbought Stochastic Strength -10.71%
Jan 14 Wide Bands Range Expansion -6.54%

Older signals for BTX ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
BioTime, Inc., a biotechnology company, focuses on regenerative medicine and blood plasma volume expanders. The company primarily focuses on regenerative medicine, which refers to therapies based on human embryonic stem cell and induced pluripotent stem cell technology designed to rebuild cell and tissue function lost due to degenerative disease or injury. It develops and markets research products in the field of stem cells, including an array of proprietary PureStem cell lines and associated ESpan culture media, HyStem hydrogels, and differentiation kits, as well as offers Hextend, a blood plasma volume expander. The company is developing Renevia, a biocompatible, implantable hyaluronan, and collagen-based matrix for cell delivery in human clinical applications; stem cell-based therapies for retinal and neural degenerative diseases; and therapies to treat orthopedic disorders, diseases, and injuries. It is also developing PanC-Dx, a non-invasive blood-based cancer screening test; and therapeutic products for cardiovascular and blood diseases and disorders. In addition, the company markets GeneCards, a human gene database. Further, it is developing an integrated database suite to complement GeneCards that would include the LifeMap database of embryonic development, stem cell research, and regenerative medicine, as well as MalaCards, the human disease database. BioTime, Inc. was founded in 1990 and is headquartered in Alameda, California.
Is BTX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 3.16
52 Week Low 0.66
Average Volume 616,211
200-Day Moving Average 2.059
50-Day Moving Average 1.341
20-Day Moving Average 1.0235
10-Day Moving Average 1.105
Average True Range 0.1081
ADX 34.86
+DI 13.2002
-DI 22.1943
Chandelier Exit (Long, 3 ATRs ) 0.8957
Chandelier Exit (Short, 3 ATRs ) 0.9843
Upper Bollinger Band 1.2198
Lower Bollinger Band 0.8272
Percent B (%b) 0.44
BandWidth 38.358574
MACD Line -0.0618
MACD Signal Line -0.086
MACD Histogram 0.0242
Fundamentals Value
Market Cap 115.8 Million
Num Shares 116 Million
EPS 0.60
Price-to-Earnings (P/E) Ratio 1.67
Price-to-Sales 81.83
Price-to-Book 1.49
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.17
Resistance 3 (R3) 1.18 1.13 1.14
Resistance 2 (R2) 1.13 1.09 1.13 1.13
Resistance 1 (R1) 1.07 1.07 1.05 1.06 1.12
Pivot Point 1.02 1.02 1.01 1.02 1.02
Support 1 (S1) 0.96 0.98 0.94 0.95 0.88
Support 2 (S2) 0.91 0.96 0.91 0.87
Support 3 (S3) 0.85 0.91 0.86
Support 4 (S4) 0.84